Early COVID-19 XBB.1.5 Vaccine Effectiveness Against
Hospitalisation Among Adults Targeted for Vaccination, VEBIS
Hospital Network, Europe, October 2023–January 2024

J 2024

Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024

ANTUNES, Liliana; Clara MAZAGATOS; Iván MARTÍNEZ-BAZ; Reinout NAESENS; Maria-Luise BORG et al.

Základní údaje

Originální název

Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024

Autoři

Vydání

Influenza and Other Respiratory Viruses, Hoboken, Wiley, 2024, 1750-2640

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30303 Infectious Diseases

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.200

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/24:00136914

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

COVID-19 XBB1.5 vaccine; Europe; SARS-CoV- 2 hospitalisation; vaccine effectiveness

Štítky

14110214, 14110516, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 4. 4. 2025 12:53, Mgr. Tereza Miškechová

Anotace

V originále

We conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 amongadult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of theeffectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS- CoV-2 hospitalisation. Vaccineeffectiveness was 49% overall, ranging between 69% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, withVE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.

Návaznosti

LM2023049, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Czech National Node to the European Clinical Research Infrastructure Network

Citovat

ANTUNES, Liliana; Clara MAZAGATOS; Iván MARTÍNEZ-BAZ; Reinout NAESENS; Maria-Luise BORG; Goranka PETROVIC; Terra FATUKASI; Ligita JANCORIENE; Ausenda MACHADO; Beatrix OROSZI; Petr HUSA; Mihaela LAZAR; Ralf DÜRRWALD; Jennifer HOWARD; Aryse MELO; Gloria PÉREZ-GIMENO; Jesús CASTILLA; Eva BERNAERT; Aušra DŽIUGYTÉ; Zvjezdana LOVRIC MAKARIC; Margaret FITZGERALD; Auksé MICKIENÉ; Veronica GOMEZ; Gergö TÚRI; Lenka SOUČKOVÁ; Alexandru MARIN; Kristin TOLKSDORF; Nathalie NICOLAY a Angela MC ROSE. Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024. Influenza and Other Respiratory Viruses. Hoboken: Wiley, 2024, roč. 18, č. 8, s. 1-7. ISSN 1750-2640. Dostupné z: https://doi.org/10.1111/irv.13360.

@article{2424818,
   author = {Antunes, Liliana and Mazagatos, Clara and MartínezandBaz, Iván and Naesens, Reinout and Borg, MariaandLuise and Petrovic, Goranka and Fatukasi, Terra and Jancoriene, Ligita and Machado, Ausenda and Oroszi, Beatrix and Husa, Petr and Lazar, Mihaela and Dürrwald, Ralf and Howard, Jennifer and Melo, Aryse and PérezandGimeno, Gloria and Castilla, Jesús and Bernaert, Eva and Džiugyté, Aušra and Lovric Makaric, Zvjezdana and Fitzgerald, Margaret and Mickiené, Auksé and Gomez, Veronica and Túri, Gergö and Součková, Lenka and Marin, Alexandru and Tolksdorf, Kristin and Nicolay, Nathalie and Rose, Angela MC},
   article_location = {Hoboken},
   article_number = {8},
   doi = {https://doi.org/10.1111/irv.13360},
   keywords = {COVID-19 XBB1.5 vaccine; Europe; SARS-CoV- 2 hospitalisation; vaccine effectiveness},
   language = {eng},
   issn = {1750-2640},
   journal = {Influenza and Other Respiratory Viruses},
   title = {Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024},
   url = {https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13360?src=getftr},
   volume = {18},
   year = {2024}
}

TY  - JOUR
ID  - 2424818
AU  - Antunes, Liliana - Mazagatos, Clara - Martínez-Baz, Iván - Naesens, Reinout - Borg, Maria-Luise - Petrovic, Goranka - Fatukasi, Terra - Jancoriene, Ligita - Machado, Ausenda - Oroszi, Beatrix - Husa, Petr - Lazar, Mihaela - Dürrwald, Ralf - Howard, Jennifer - Melo, Aryse - Pérez-Gimeno, Gloria - Castilla, Jesús - Bernaert, Eva - Džiugyté, Aušra - Lovric Makaric, Zvjezdana - Fitzgerald, Margaret - Mickiené, Auksé - Gomez, Veronica - Túri, Gergö - Součková, Lenka - Marin, Alexandru - Tolksdorf, Kristin - Nicolay, Nathalie - Rose, Angela MC
PY  - 2024
TI  - Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024
JF  - Influenza and Other Respiratory Viruses
VL  - 18
IS  - 8
SP  - 1-7
EP  - 1-7
PB  - Wiley
SN  - 17502640
KW  - COVID-19 XBB1.5 vaccine
KW  - Europe
KW  - SARS-CoV- 2 hospitalisation
KW  - vaccine effectiveness
UR  - https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13360?src=getftr
N2  - We conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 amongadult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of theeffectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS- CoV-2 hospitalisation. Vaccineeffectiveness was 49% overall, ranging between 69% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, withVE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.
ER  -

ANTUNES, Liliana; Clara MAZAGATOS; Iván MARTÍNEZ-BAZ; Reinout NAESENS; Maria-Luise BORG; Goranka PETROVIC; Terra FATUKASI; Ligita JANCORIENE; Ausenda MACHADO; Beatrix OROSZI; Petr HUSA; Mihaela LAZAR; Ralf DÜRRWALD; Jennifer HOWARD; Aryse MELO; Gloria PÉREZ-GIMENO; Jesús CASTILLA; Eva BERNAERT; Aušra DŽIUGYTÉ; Zvjezdana LOVRIC MAKARIC; Margaret FITZGERALD; Auksé MICKIENÉ; Veronica GOMEZ; Gergö TÚRI; Lenka SOUČKOVÁ; Alexandru MARIN; Kristin TOLKSDORF; Nathalie NICOLAY a Angela MC ROSE. Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024. \textit{Influenza and Other Respiratory Viruses}. Hoboken: Wiley, 2024, roč.~18, č.~8, s.~1-7. ISSN~1750-2640. Dostupné z: https://doi.org/10.1111/irv.13360.

Přehled o publikaci